(S)-EB-FAPI-B2

• UNSPSC Description:

  (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy[1][2].

• Target Antigen:

  Radionuclide-Drug Conjugates (RDCs)

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/s-eb-fapi-b2.html

• Smiles:

  O=S(O)(C1=CC(S(=O)(O)=O)=C(N)C2=C1C=CC(/N=N/C3=C(C=C(C4=CC(C)=C(C=C4)NC([C@H](CCCCNC(CCOCCOCCC(N5CCN(CC5)CCCOC6=CC7=C(N=CC=C7C(NCC(N8[C@@H](CCC8)C#N)=O)=O)C=C6)=O)=O)NC(CN9CCN(CCN(CCN(CC9)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)C=C3)C)=C2O)=O

• Molecular Weight:

  1677.85

• References & Citations:

  [1]Chen XY, et al. Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof. CN113582975A. 2021 November 02.|[2]Wen X, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022 Jan 1;12(1):422-433.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 1

• CAS Number:

  2740747-99-1